Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
Public ClinicalTrials.gov record NCT01544595. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 4 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
Study identification
- NCT ID
- NCT01544595
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 1,147 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Secukinumab (AIN457) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 18, 2012
- Primary completion
- Jun 25, 2017
- Completion
- Jun 25, 2017
- Last update posted
- Dec 19, 2018
2012 – 2017
United States locations
- U.S. sites
- 37
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35205 | — |
| Novartis Investigative Site | Birmingham | Alabama | 35233 | — |
| Novartis Investigative Site | Phoenix | Arizona | 85013 | — |
| Novartis Investigative Site | Phoenix | Arizona | 85032 | — |
| Novartis Investigative Site | Los Angeles | California | 90045 | — |
| Novartis Investigative Site | Oceanside | California | 92056 | — |
| Novartis Investigative Site | Pasadena | California | 91105 | — |
| Novartis Investigative Site | San Diego | California | 92103 | — |
| Novartis Investigative Site | San Diego | California | 92123 | — |
| Novartis Investigative Site | Colorado Springs | Colorado | 80915 | — |
| Novartis Investigative Site | Snellville | Georgia | 30078 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46256 | — |
| Novartis Investigative Site | Topeka | Kansas | 66606 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40241 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40291 | — |
| Novartis Investigative Site | Ann Arbor | Michigan | 48109 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68144 | — |
| Novartis Investigative Site | New York | New York | 10029 | — |
| Novartis Investigative Site | Rochester | New York | 14623 | — |
| Novartis Investigative Site | High Point | North Carolina | 27262 | — |
| Novartis Investigative Site | Warren | Ohio | 44483 | — |
| Novartis Investigative Site | Oregon City | Oregon | 97045 | — |
| Novartis Investigative Site | Portland | Oregon | 97210 | — |
| Novartis Investigative Site | Portland | Oregon | 97223 | — |
| Novartis Investigative Site | Duncansville | Pennsylvania | 16635 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| Novartis Investigative Site | Johnston | Rhode Island | 02919 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29407 | — |
| Novartis Investigative Site | Kingsport | Tennessee | 37660 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37203 | — |
| Novartis Investigative Site | Austin | Texas | 78759 | — |
| Novartis Investigative Site | Dallas | Texas | 75231 | — |
| Novartis Investigative Site | Dallas | Texas | 75246-1613 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | San Antonio | Texas | 78229 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84117 | — |
| Novartis Investigative Site | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 145 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01544595, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2018 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01544595 live on ClinicalTrials.gov.